Effect of HDL, from Japanese white rabbit administered a new cholesteryl ester transfer protein inhibitor JTT-705, on cholesteryl ester accumulation induced by acetylated low density lipoprotein in J774 macrophage.
We have previously reported a potent and specific cholesteryl ester transfer protein (CETP) inhibitor JTT-705 was a potentially anti-atherogenic compound (Nature 406 (2000) 203). In the present study, we investigated in vitro how this compound affects properties of high density lipoprotein (HDL) in Japanese white (JW) rabbits in terms of reverse cholesterol transport in J774 macrophages. Plasma HDL-cholesterol (C) level was significantly higher in the rabbits administered JTT-705 than in control rabbits on days 3 and 7. Both HDL(2) and HDL(3)-C levels were also significantly higher in JTT-705-administered rabbits than in control rabbits. During this period, plasma CETP activity was kept lower in JTT-705-administered rabbits than in controls. To determine how this compound affects the property of HDL particles, we investigated the C efflux induced by HDL from JTT-705-administered and control rabbits in J774 macrophages. Cholesterol ester (CE) concentration in J774 macrophages was reduced in proportion with increasing concentration of the added HDL to the culture media for J774 macrophages in both groups, suggesting that the HDL from JTT-705-administered rabbits was able to reduce CE concentration in J774 macrophages as efficiently as that from control rabbits. This result, together with the finding that the absolute HDL concentration increased in JW rabbits administered this CETP inhibitor, suggests that treatment with this new compound causes a beneficial effect on lipid metabolism in terms of anti-atherogenicity.
Kobayashi
Junji
J
Second Department of Internal Medicine, Chiba University School of Medicine, 1-8-1 Inohana, Chuo-Ku, Chiba 260 8670, Japan. junjiko@intmed02.m.chiba-u.ac.jp
Okamoto
Hiroshi
H
Otabe
Masako
M
Bujo
Hideaki
H
Saito
Yasushi
Y
D000577:Amides; D000818:Animals; D002352:Carrier Proteins / Q000097:blood / Q000187:drug effects*; D053480:Cholesterol Ester Transfer Proteins; D002788:Cholesterol Esters / Q000096:biosynthesis* / Q000097:blood; D008076:Cholesterol, HDL / Q000097:blood / Q000187:drug effects*; D004305:Dose-Response Relationship, Drug; D004952:Esters; D006023:Glycoproteins; D007564:Japan; D008077:Lipoproteins, LDL / Q000187:drug effects*; D008264:Macrophages / Q000187:drug effects* / Q000378:metabolism*; D008297:Male; D023421:Models, Animal; D011817:Rabbits; D013438:Sulfhydryl Compounds / Q000008:administration & dosage* / Q000037:antagonists & inhibitors*; D014280:Triglycerides / Q000097:blood
D000577:Amides; D002352:Carrier Proteins; D053480:Cholesterol Ester Transfer Proteins; D002788:Cholesterol Esters; D008076:Cholesterol, HDL; D004952:Esters; D006023:Glycoproteins; D008077:Lipoproteins, LDL; D013438:Sulfhydryl Compounds; D014280:Triglycerides; C032629:acetyl-LDL; C411602:dalcetrapib